Jeffrey Schell
Managing Director, CTO, Patent Attorney
Description:
Jeff's mission is to transform innovative concepts into companies. In 2015, Jeff leveraged the valuable IP that he cultivated and developed to raise three million dollars in debt financing to acquire medical device company TranS1’s assets out of a failed merger. Within a few years of rebuilding TranS1 as CEO, ColoradoBiz Magazine named TranS1 one of the top 250 companies in Colorado by revenue. The Denver Post also named TranS1 Denver's "Most Innovative Workplace" in 2016. Further, the Colorado Technology Association named TranS1 a nominee for "Company of the Year." Under Jeff's leadership, Orthopedics This Week awarded TranS1 with the 2017 Spine Technology Award. In 2018, Jeff had a successful exit from TranS1. In 2018, Jeff took a significant stake in Proov - evolving its underlying tech into multiple patent pending products and an emerging brand in women's health - and he continues to play a leadership role. Soon thereafter, the company was featured in Forbes and won the “Best Family Tech at CES†award given by Parents Magazine. In 2019, the company won SXSW Startup of the Year. In 2020, the company raised several million dollars in VC and grant funding, gained distribution at leading retailers, won the coveted “Colorado Companies to Watch†recognition, and in 2021 grew to become named as one of the Denver Business Journal’s “25 largest biotechnology companies in Colorado.†Proov closed a $10MM Series A with the involvement of multiple prominent venture capital firms in 2021. In 2019, top tier law firm Hall Estill acquired the rights to the Rocky Mountain Patent brand. Jeff now leads the Ventures Growth practice for Hall Estill. In addition to building intellectual property strategies with the Rocky Mountain Patent team, Jeff now advises, operates and invests in multiple companies. Jeff is the former President of TiE Denver and remains heavily engaged with investment and startup advisory groups including Rockies Venture Club, BoomTown, TechStars and Prime Health. Jeff attended Northwestern University, graduating with degrees in Industrial Engineering & Management Sciences and Economics in 2004. He subsequently earned his JD and masters degrees in International Studies and Medical Informatics. Jeff separately studied economics at Harvard University, and in 2007, was a delegate at the Harvard China-India Development & Relations Symposium. ColoradoBiz Magazine named Jeff one of the 25 "Most Influential Young Professionals in Colorado" and he is a "40 under 40" honoree. He was also a finalist for the Denver Post's "Colorado Innovator of the Year" and "Denver Trailblazer" awards. In 2017, Denver Mayor Michael Hancock invited Jeff to participate in Denver's official trade delegation to South Africa and Kenya.
Summary:
Jeff's mission is to transform innovative concepts into companies. In 2015, Jeff leveraged the valuable IP that he cultivated and develo...
Number of Registered Investments:2
Contact Details:
- Address: Denver, Colorado, United States
- No email is provided
Location:Denver, Colorado, United States
Email is Not Provided
Phone Number:Denver, Colorado, United States
Updated August 2023. This content was crafted by an associate of Najafi Capital (“Najafi”) and is presented strictly for informational objectives. The details on this page neither advocate for nor dissuade the subscription, acquisition, or sale of any security or offering. The material Najafi evaluates for project owner screening and due diligence stems directly from the project owner presenting the investment opportunity. While Najafi perceives the information to have been sourced from trustworthy channels, there is no absolute assurance, warranty, or representation concerning its authenticity. Najafi renounces any liability regarding content provided by the project owner, inclusive of the data utilized to fulfill elements outlined on this page. Najafi is not accountable for the precision, legality, or the affirmation of subsequent details shared by the project owner.
Prospective investors are urged to perform their individual due diligence and authenticate the provided data. Investing inherently encompasses risks, inclusive of the potential loss of capital invested. All investors are recommended to ponder over these aspects in tandem with a chosen professional consultant to ascertain the suitability of an investment.